American Journal of Cardiology
Volume 105, Issue 1, Supplement , Pages 1A-2A , 4 January 2010

Introduction

  • Jeffrey L. Probstfield, MD

      Affiliations

    • Clinical Trials Service Unit, Department of Medicine/Cardiology, University of Washington School of Medicine, Seattle, Washington, USA
    • Corresponding Author InformationAddress for reprints: Jeffrey L. Probstfield, MD, University of Washington Medical Center, 1959 NE Pacific St, Campus Box 356422, Seattle, Washington 98195-6422, USA
    • ,
  • Michael A. Weber, MD

      Affiliations

    • State University of New York Downstate College of Medicine, Brooklyn, New York, USA

References 

  1. Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 2010;105(suppl):3A–8A
  2. Jeffrey L, Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol. 2010;105(suppl):9A–19A
  3. Bakris G. There effects of renin-angiotensin antagonists beyond blood pressure control?. Am J Cardiol. 2010;105(suppl):20A–28A
  4. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol. 2010;105(suppl):29A–34A
  5. Weber MA. Telmisartan in high-risk cardiovascular patients. Am J Cardiol. 2010;105(suppl):35A–42A

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 This work was supported by Boehringer Ingelheim GmbH.

PII: S0002-9149(09)02480-1

doi: 10.1016/j.amjcard.2009.10.005

American Journal of Cardiology
Volume 105, Issue 1, Supplement , Pages 1A-2A , 4 January 2010

Article Tools